Conolidine’s analgesic consequences stem from its interaction with non-opioid pain pathways. Compared with opioids, which bind to µ-opioid receptors in the central anxious process, conolidine modulates alternate molecular targets. A Science Advancements analyze found that conolidine interacts While using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide avail... https://anni642fhi3.luwebs.com/profile